All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM | DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $61,366 | $58,739 | $39,721 | $45,811 | $44,351 | $37,417 |
| Cost of Revenue | $11,120 | $10,633 | $7,498 | $8,268 | $12,391 | $12,437 |
| Gross Profit | $50,246 | $48,106 | $32,224 | $37,543 | $31,960 | $24,980 |
| Total Operating Expenses | $36,275 | $34,779 | $24,693 | $28,821 | $27,448 | $25,119 |
| Operating Income | $13,971 | $13,327 | $7,530 | $8,722 | $4,512 | -$139 |
| Non-Operating | ||||||
| Net Interest Expense | -$1,746 | -$1,614 | -$1,236 | -$1,589 | -$1,330 | -$1,276 |
| Income Tax Expense | $2,133 | $2,169 | $1,212 | $938 | -$792 | -$380 |
| Net Income | ||||||
| Net Income | $10,453 | $10,233 | $5,172 | $5,961 | $3,293 | $115 |
| Per Share Data | ||||||
| Revenue Per Share | $39.34 | $37.90 | $34.89 | $23.86 | $23.12 | $21.29 |
| EPS (Basic) | $6.73 | $6.60 | $4.54 | $3.84 | $2.12 | $0.08 |
| EPS (Diluted) | $6.70 | $6.54 | $4.50 | $3.81 | $2.11 | $0.08 |
| Shares Outstanding | 1.56B | 1.55B | 1.14B | 1.92B | 1.92B | 1.76B |
| Dividends Per Share | $3.17 | $3.17 | $3.10 | $2.89 | $2.89 | $2.84 |
AstraZeneca (AZN.XLON) financials: revenue, profit and margins
AstraZeneca (AZN.XLON) generated about $61.4 billion in revenue and $10.5 billion in net income (a 17.0% net margin) over the trailing twelve months, growing at roughly 11.9% a year. Figures are from company filings; this is analysis, not investment advice.
Frequently asked
What is AstraZeneca's (AZN.XLON) revenue?+
AstraZeneca generated about $61.4 billion in revenue over the trailing twelve months. Revenue has grown at roughly 11.9% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is AstraZeneca profitable?+
Yes, AstraZeneca reported about $10.5 billion in net income over the trailing twelve months, a net profit margin of roughly 17.0%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
What are AstraZeneca's profit margins?+
AstraZeneca runs a gross margin of about 81.9%, an operating margin of about 22.8%, a net margin of about 17.0%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
How fast is AstraZeneca growing?+
AstraZeneca's revenue has compounded at roughly 11.9% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside AZN.XLON's margins and free cash flow. This is analysis from company filings, not investment advice.
Peers
Drug Manufacturers - General · Pick stocks to compare with AZN.XLON
Held by ETFs
AZN.XLON is in 202 US ETFs. The largest of them, with AZN.XLON's weight in each:
Vanguard Total International Stock ETFVXUS0.54%of the fund
iShares Core MSCI EAFE ETFIEFA1.03%of the fund
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing AZN.XLON
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.